Release Date: July 11, 2025

Expiration Date: July 11, 2026

Activity Overview

This educational activity is an archive of the live presentation held on Sunday, June 1, 2025.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is directed toward oncologists, medical oncologists, and other HCPs involved in the treatment and management of EGFR-NSCLC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Discuss guideline-recommended strategies for biomarker testing to detect EGFR mutations in patients with metastatic NSCLC
Outline current and emerging treatment strategies for EGFR-mutated metastatic NSCLC
Integrate recent data and guideline-based recommendations when developing personalized care plans for patients with metastatic, EGFR-mutated NSCLC
Identify appropriate strategies for the prevention and management of toxicities associated with EGFR-targeting therapies for metastatic NSCLC

Balazs Halmos, MD, MS

Professor of Clinical Medicine
Director, Thoracic/Head and Neck Oncology
Director, Clinical Cancer Genomics
Albert Einstein College of Medicine/Montefiore Medical Center
Bronx, NY

Disclosures: Consultant: Apollomics, AstraZeneca, BMS, Boehringer Ingelheim, Daiichi, Eli-Lilly, Genentech, GSK, Johnson & Johnson, Merck, Pfizer, Takeda; DSMC: Apollomics, BMS, City of Hope, Nuvalent, TPT, eFECTOR; Research grant (paid to institution): AbbVie, Advaxis, Amgen, Arrivent, AstraZeneca, Beigene, Black Diamond Therapeutics, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Forward Pharma, GSK, Janssen, Merck, Numab, Pfizer

Enriqueta Felip, MD, PhD

Professor of Medicine, Universitat Autònoma de Barcelona (UAB)
Section in Chief, Medical Oncology Department
Director Thoracic Oncology Unit
Vall d’Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Disclosures: Consulting Fee: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daichii-Sankyo, F. Hoffmann-La Roche, Gilead, Glaxo Smith Kline, Janssen, Johnson & Johnson, Merck Sharp & Dohme, Novartis, Pierre Fabre, Pfizer, Regeneron, Sanofi, Turning Point; Independent Member of the Board: Grifols; Speaker’ Bureau: Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Daiichi-Sankyo, Eli Lilly, F. Hoffmann-La Roche, Genentech, Gilead, Janssen, Johnson & Johnson, Medical Trends, Medscape, Merck Serono, Merck Sharp & Dohme, Novartis, Peervoice, Pfizer, Regeneron, Takeda; Support for attending meetings/travel: AstraZeneca, Johnson & Johnson, Roche

Julia Rotow, MD

Assistant Professor
Harvard Medical School
Clinical Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Consultant: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squib, Daiichi-Sankyo, Genentech, Gilead, Jazz, Johnson & Johnson, Merus, Novocure, Pfizer; Contracted for research (to institution): AbbVie, Altor Bioscience, AstraZeneca, Bicycle Therapeutics, BioAtla, Black Diamond Therapeutics, Blueprint Medicines, Duality, Enliven Therapeutics, EpimAb, Immunity Bio, LOXO Oncology, ORIC Pharmaceuticals, RedCloud Bio, Regeneron, Summit, Synthekine; Honoraria: AstraZeneca, Daiichi-Sankyo, Pfizer

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Black Diamond Therapeutics.

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS

Enriqueta Felip, MD, PhD

Julia Rotow, MD

GET STARTED WITH THIS PROGRAM:

You Also Might Like...

Cure to Cancer Survivorship: A New Era of Biomarkers, Interventions, and Care Models

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities